| 2020 | 2021 (projected) | Interest Expense | 21.62 K | 25.93 K | Gross Profit | 41.57 M | 44.85 M |
Corbus Pharmaceuticals (NASDAQ:CRBP) high volatility trend continues
 | By Ellen Johnson | Macroaxis Story |
Given the investment horizon of 60 days Corbus Pharmaceuticals is expected to generate 6.92 times more return on investment than the market. However, the company is 6.92 times more volatile than its market benchmark. It trades about 0.25 of its potential returns per unit of risk. The DOW is currently generating roughly 0.21 per unit of risk. While some of us are excited about healthcare space, it makes sense to recap Corbus Pharmaceuticals in greater detail to make a better estimate of its risk and reward. We will evaluate if Corbus Pharmaceuticals' current volatility will continue into February. The recent Corbus risk factors may impact the value of the stock as we estimate Corbus Pharmaceuticals as currently fairly valued. The real value is approaching 1.76 per share.
Macroaxis uses a strict editorial review process to publish stories and blog posts. Our publishers support our company and may receive a small commission when the partner links or references are utilized. Commissions do not affect the opinions or evaluations of our editorial team. The information our editors and media partners deliver is confidential and licensed for your sole use as a Macroaxis user. We reserve all rights to the content of this article, and therefore copying or distributing this story in whole or in part is strictly prohibited.
Reviewed by Gabriel Shpitalnik
Corbus Pharmaceuticals currently holds 26.18 M in liabilities with Debt to Equity (D/E) ratio of 0.9, which is about average as compared to similar companies. This firm has a current ratio of 2.02, suggesting that it is liquid enough and is able to pay its financial obligations when due. Corbus Pharmaceuticals holds a performance score of 17 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of 0.4845, which signifies possible diversification benefits within a given portfolio. Let's try to break down what Corbus's beta means in this case. As returns on the market increase, Corbus Pharmaceuticals returns are expected to increase less than the market. However, during the bear market, the loss on holding Corbus Pharmaceuticals will be expected to be smaller as well. Although it is essential to pay attention to Corbus Pharmaceuticals historical returns, it is also good to be reasonable about what you can do with equity current trending patterns. Our philosophy towards foreseeing future performance of any stock is to look not only at its past charts but also at the business as a whole, including all fundamental and technical indicators. To evaluate if Corbus Pharmaceuticals Holdings expected return of 1.71 will be sustainable into the future, we have found twenty-one different technical indicators, which can help you to check if the expected returns are sustainable. Use Corbus Pharmaceuticals standard deviation, maximum drawdown, as well as the relationship between the Maximum Drawdown and expected short fall to analyze future returns on Corbus Pharmaceuticals. Volatility is a rate at which the price of Corbus Pharmaceuticals or any other equity instrument increases or decreases for a given set of returns. It is measured by calculating the standard deviation of the annualized returns over a given period of time and shows the range to which the price of Corbus Pharmaceuticals may increase or decrease. In other words, similar to Corbus's beta indicator, it measures the risk of Corbus Pharmaceuticals and helps estimate the fluctuations that may happen in a short period of time. So if prices of Corbus Pharmaceuticals fluctuate rapidly in a short time span, it is termed to have high volatility, and if it swings slowly in a more extended period, it is understood to have low volatility. Please read more on our technical analysis page.
How important is Corbus Pharmaceuticals's Liquidity
Corbus Pharmaceuticals financial leverage refers to using borrowed capital as a funding source to finance Corbus Pharmaceuticals Holding ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Corbus Pharmaceuticals financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Financial leverage can amplify the potential profits to Corbus Pharmaceuticals' owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of Corbus Pharmaceuticals' financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets). Please check the breakdown between Corbus Pharmaceuticals's total debt and its cash.
Corbus Pharmaceuticals Gross Profit
Corbus Pharmaceuticals Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing Corbus Pharmaceuticals previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show Corbus Pharmaceuticals Gross Profit growth over the last 10 years. Please check Corbus Pharmaceuticals' gross profit and other fundamental indicators for more details.
Corbus Pharmaceuticals Volatility Drivers
Corbus Pharmaceuticals unsystematic risk is unique to Corbus Pharmaceuticals and usually not directly affected by the market or economic environment. An example of unsystematic risk is the possibility of poor earnings or a layoff due to coronavirus. One may mitigate nonsystematic risk by buying different securities in the same industry or by buying in different sectors. For example, if you have a position in Corbus Pharmaceuticals you can also buy Trevi Therapeutics. You can also mitigate this risk by investing in the health care sector as well as in companies having nothing to do with it. This type of risk is also called diversifiable risk and can be understood from analyzing Corbus Pharmaceuticals important indicators over time. Here we run a correlation analysis between relevant fundamental ratios over at least ten year period to find a relationship in the way they react to changes in Corbus Pharmaceuticals income statement and balance sheet. Here are more details about Corbus volatility.Click cells to compare fundamentals
Breaking down Corbus Pharmaceuticals Further
The company reported the previous year's revenue of 5.85 M. Net Loss for the year was (129.24 M) with loss before overhead, payroll, taxes, and interest of (53.46 M).
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Ellen Johnson do not own shares of Corbus Pharmaceuticals Holding. Please refer to our Terms of Use for any information regarding our disclosure principles.